Evidence map›Paper›PMID 40958871›Full record

ArticleFrontiers in oncology2025

MEX3A is a diagnostic, independent prognostic biomarker and a promising therapeutic target in glioblastoma.

Francesca Bufalieri, Daniele Armocida, Antonino Cucinotta, Pietro Familiari, Laura Di Magno, Alessandra Serraino, Gennaro Adabbo, Francesca Agnoli, Ludovica Lospinoso Severini, Manila Antonelli and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Francesca Bufalieri *Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Daniele Armocida *Experimental Neurosurgery Unit, IRCCS "Neuromed", Pozzilli, Italy.
Antonino CucinottaDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Pietro FamiliariNeurosurgery Division, Human Neurosciences Department, Sapienza University of Rome, Rome, Italy.
Laura Di MagnoDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Alessandra SerrainoNeurosurgery Division, Human Neurosciences Department, Sapienza University of Rome, Rome, Italy.
Gennaro AdabboDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Francesca AgnoliDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Ludovica Lospinoso SeveriniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Manila AntonelliExperimental Neurosurgery Unit, IRCCS "Neuromed", Pozzilli, Italy.
Alessandro FratiNeurosurgery Division, Human Neurosciences Department, Sapienza University of Rome, Rome, Italy.
Gianluca CanettieriDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Paola InfanteDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Antonio SantoroNeurosurgery Division, Human Neurosciences Department, Sapienza University of Rome, Rome, Italy.
Luca D'AngeloNeurosurgery Division, Human Neurosciences Department, Sapienza University of Rome, Rome, Italy.
Lucia Di MarcotullioDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Gliomas are the most common malignant brain tumors with a poor prognosis. Despite advances in molecular profiling, no targeted therapies significantly improve survival. Recently, it has been demonstrated that high expression of Muscle Excess 3A (MEX3A) correlates with poor overall survival (OS) in gliomas, generating interest in its potential as a biomarker and therapeutic target. This study analyzes the correlation between Methods: We performed a retrospective study on a consecutive series of surgically-treated glioma patients. The values of Results: Elevated MEX3A expression associates with more severe clinicopathological and molecular features of glioma patients. MEX3A exhibits high diagnostic accuracy (AUC > 0.9) and correlates with poor OS (HR=2.068, p=0.0018) and progression-free survival (PFS) (HR=2.209, p=0.0005) in GB. Multivariate Cox regression identified MEX3A as an independent prognostic factor for OS and PFS. Notably, Conclusions: Our findings highlight MEX3A as a novel diagnostic and prognostic biomarker and a promising therapeutic target for GB.

Indexed as

biomarkergliomasMEX3Aneuro-oncologytherapeutic target

Identifiers

PMID40958871
PMCPMC12433882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.